Endometrial Endometrioid Adenocarcinoma Clinical Trial
Official title:
A Pilot, Multicenter, Single Arm, Open Label, Surgical Window of Opportunity Study of Abemaciclib and Letrozole for Endometrioid Adenocarcinoma of the Endometrium
This early phase I trial studies how well abemaciclib and letrozole work in treating patients with endometrial cancer and determines whether there are changes in patients' cancer cell biomarkers (a genetic feature or specific protein) for cell growth before and after treatment. Antihormone therapy with aromatase inhibitors, such as letrozole, may lessen the amount of estrogen made by the body. Abemaciclib blocks the activities of a class of proteins called cyclin-dependent kinase, which are involved in cell duplication. Giving letrozole and abemaciclib together may slow down cancer cell growth in patients with endometrial cancer.
PRIMARY OBJECTIVES: I. To determine whether there are changes in Ki-67 expression from the pretreatment specimen (e.g. biopsy or dilation and curettage [D&C]) to the post-treatment hysterectomy specimen following treatment with letrozole and abemaciclib. SECONDARY OBJECTIVES: I. To determine the proportion of tumors with complete cell cycle arrest (CCCA) response as measured by Ki-67 expression between the pre-treatment tumor and the posttreatment tumor. II. To identify biological characteristics of tumors (e.g. mismatch repair [MMR] status, PTEN mutational status, etc.) correlating with decreased Ki-67 expression induced by the letrozole and abemaciclib combination. III. To determine the frequency of adverse events associated with use of abemaciclib and letrozole. EXPLORATORY OBJECTIVES: I. To evaluate the correlation of the expression of Ki-67 with that of cyclin D1, p16, pRB, and PTEN as well as with MMR deficiency. OUTLINE: Patients receive letrozole orally (PO) once daily (QD) and abemaciclib PO twice daily (BID) on days 1-14. Patients then undergo standard of care hysterectomy on day 15. After completion of study treatment, patients are followed up at 30 days and at 2 and 6 weeks after surgery. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02728258 -
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT05112601 -
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03914612 -
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
|
Phase 3 | |
| Completed |
NCT04972682 -
[SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer
|
N/A | |
| Recruiting |
NCT03422198 -
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
|
Phase 3 | |
| Recruiting |
NCT05498597 -
AMT-151 in Patients With Selected Advanced Solid Tumours
|
Phase 1 | |
| Withdrawn |
NCT03677024 -
Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas
|
N/A | |
| Active, not recruiting |
NCT02020707 -
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
|
Phase 1 | |
| Recruiting |
NCT05950464 -
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04214067 -
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
|
Phase 3 | |
| Completed |
NCT00478426 -
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
|
Phase 2 |